Skip to search formSkip to main contentSkip to account menu

Privigen

Known as: Venimmune 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIM A pharmacoeconomic analysis of direct costs on treatment with high dose intravenous immunoglobulins (IVIG) and plasmapheresis… 
2014
2014
Activated clotting factor FXI (FXIa) has been postulated to play a significant role in thromboembolic events potentially… 
2014
2014
IntroductionHemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal… 
2014
2014
High dose intravenous immunoglobulin (IVIG) is an established treatment for various neuromuscular disorders. Recently, cases of… 
Highly Cited
2013
Highly Cited
2013
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10… 
2009
2009
Abstract Intravenous immunoglobulin (IVIG) has become a mainstay of treatment for acute and chronic immune thrombocytopenic… 
2009
2009
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… 
2009
2009
2009
Background and Objectives  IgPro10 (Privigen©) is a new liquid intravenous immunoglobulin (IVIG) product that is formulated with…